methylome sequencing
The Canadian company plans to test the clinical utility of its targeted 90-marker panel in monitoring patient response to therapy.
The company raised $60 million last week and will use the funding to develop and validate its DNA methylation-based tests and classifier algorithm.
Liquid Biopsy Startup Adela Launches With $60M Series A Financing Round
The Toronto-based company will use the funding to commercialize its cell-free DNA methylation sequencing technology as an early cancer detection test.
Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider
Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.
Data Supports Singlera's PanSeer Test as Company Narrows Focus to Colorectal Cancer Detection
The company recently had a second pre-submission with FDA and expects to begin a prospective trial of its test in the second half of this year.